Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,682 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06775743RecruitingPhase 2
Combination therapy and radiation for EGFR-mutant lung cancer after resistance
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06776952RecruitingPhase 3
Study of XNW5004 for relapsed or refractory peripheral T-cell lymphoma
This study tests a new oral tablet called XNW5004 for people with peripheral T-cell lymphoma (a type of blood cancer) that has come back or not responded to prior treatments. The goal is to see if this drug can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 3 weeks–2 months - NCT06777979RecruitingPhase 1
CAR T cell therapy for children with hard-to-treat leukemia
This trial tests a special kind of immune cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It is for children and teens whose leukemia has come back multiple times or has not responded to standard treatment.
Memphis, TennesseeAges Up to 21 years - NCT06781515Recruiting
Hairy cell leukemia disease burden study
This study watches the course of hairy cell leukemia (HCL) in different phases—when first diagnosed, after it comes back, or long after successful treatment. The goal is to better understand the disease and plan future care.
Bologna, BolognaAges 18 years+ - NCT06782789Recruiting
Study of Tafasitamab and Lenalidomide for aggressive B-cell lymphoma
This study looks back at medical records of people with relapsed or refractory diffuse large B-cell lymphoma who received a combination of two drugs (tafasitamab and lenalidomide) through a special access program. The goal is to learn how well the treatment worked and what side effects occurred.
Bologna, BolognaAges 18 years+ - NCT06783348RecruitingPhase 2
Radioactive treatment for advanced kidney cancer
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
CaenAges 18–100 - NCT06785519RecruitingEarly Phase 1
CAR-T cell therapy for stubborn lupus kidney disease
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06786468Recruiting
Early palliative care for advanced lung cancer
This study tests whether adding early palliative care from a specialist improves well-being for people starting treatment for advanced non-small cell lung cancer. It compares standard cancer care alone to standard care plus early palliative care.
BangkokAges 18 years+ - NCT06786533RecruitingPhase 1
CAR-T cells for hard-to-treat AML
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
Houston, TexasAges 12 years+ - NCT06787560RecruitingEarly Phase 1
CAR-T cells and stem cell transplant for blood diseases
This trial tests a new approach for people with non-cancerous blood and immune system diseases. It uses your own engineered immune cells (CAR-T cells) to prepare your body for a stem cell transplant from a relative.
Hangzhou, ZhejiangAges Any age - NCT06787989RecruitingPhase 1
BCMA-CD19 car T cell therapy for immune thrombocytopenia with autoimmune diseases
This trial tests a personalized cell therapy (CAR T cells) that targets two proteins (BCMA and CD19) on immune cells to treat low platelet counts (thrombocytopenia) that haven't improved with other treatments and are linked to autoimmune diseases like lupus or Sjogren's. The goal is to see if this therapy can safely raise your platelet levels and reduce bleeding symptoms.
Chengdu, SichuanAges 18–60 - NCT06788652Recruiting
Study of Liso-cel for mantle cell lymphoma after market approval
This study looks at patients with mantle cell lymphoma who have already received a treatment called lisocabtagene maraleucel (Liso-cel) as part of standard care. It helps researchers understand how well the therapy works in real-world use.
Milwaukee, WisconsinAges 18 years+ - NCT06792253RecruitingPhase 3
BEBT-908 plus rituximab for relapsed large B-cell lymphoma
This study tests a new drug, BEBT-908, combined with rituximab for people with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment that included a CD20 antibody. The goal is to see if this new combination works better than standard care.
Beijing, Beijing MunicipalityAges 18–75 - NCT06800339RecruitingPhase 1
Immunotherapy and radiation before surgery for lung cancer
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
Baltimore, MarylandAges 18 years+ - NCT06803875RecruitingPhase 1/Phase 2
CAR T cells for relapsed high-risk neuroblastoma
This trial is testing a new type of immunotherapy called hALK.CAR T cells for children and young adults with high-risk neuroblastoma that has come back or not responded to standard treatment. The goal is to see if these specially engineered cells can find and destroy the cancer cells.
Boston, MassachusettsAges 1–29 - NCT06806033RecruitingPhase 2
New drug combo for relapsed aggressive B-cell lymphoma
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Anchorage, AlaskaAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+ - NCT06815003RecruitingPhase 2
Preventing Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Duarte, CaliforniaAges 18–80 - NCT06815432RecruitingPhase 1
CAR T cells for recurrent glioblastoma that makes GPC3
This trial tests a treatment made from your own immune cells, called CAR T cells, which are engineered to find and attack brain tumor cells that have a marker called GPC3. It is for patients whose glioblastoma has come back and who are already scheduled to have another surgery to remove the tumor.
Houston, TexasAges 21–70 - NCT06818266RecruitingPhase 3
Tocilizumab for severe chest crisis in sickle cell disease
This trial tests if the drug tocilizumab can help treat acute chest syndrome, a serious lung complication of sickle cell disease. It is for people with sickle cell disease who are hospitalized and need oxygen or breathing support. The study compares tocilizumab to a placebo to see if it speeds up recovery.
ParisAges 2 years+ - NCT06821685RecruitingPhase 1
Natural killer cell therapy for infertility and pregnancy problems
This study tests a treatment using your own immune cells (natural killer cells) to improve pregnancy chances. It's for women with infertility, repeated miscarriages, or other pregnancy complications linked to abnormal natural killer cell function.
Nanjing, JiangsuAges 22–40 - NCT06823219Recruiting
Long-term endurance training for sickle cell disease
This study tests whether a long-term endurance exercise program can improve physical fitness, reduce complications, and enhance quality of life for people with sickle cell disease. It is designed for patients whose condition is stable but who have had at least one pain crisis in the last three years.
CréteilAges 15 years+ - NCT06823596Recruiting
HIV treatment study switching to efavirenz
This study tests whether switching to a medication called efavirenz can help control HIV. It is for people who have been on stable HIV treatment for years but still have low levels of virus in their blood.
Toronto, OntarioAges 18–89 - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,682 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.